A Primary Central Nervous System T Cell Lymphoma in a Renal Transplant Patient

Hacker, Steven M.; Knight, Bradley P.; Lunde, Norman M.; Gratiot-deans, Jean; Sandler, Howard M.; Leichtman, Alan B.

doi:10.1097/00007890-199203000-00042

Cited by 16 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of lymphoproliferative disorders developing after solid organ transplantation are phenotypically B cell and related to EBV infection. PTLD of T‐cell lineage have been described mostly as case reports ( Lippman et al , 1987 ; Tsurumi et al , 1992 ; Rostaing et al , 1995 ; Garvin et al , 1988 ; Kemnitz et al , 1990 ; Pascual et al , 1992 ; Hacker et al , 1992 ; Audovin et al , 1989 ; Ross et al , 1994 ) or included in larger series involving primarily B‐cell PTLD ( Leblond et al , 1995 ; Birkeland et al , 1995 ). For the most part these T‐cell disorders are not well characterized but appear to include a heterogenous mixture of clinically, morphologically and phenotypically variable disorders.…”

Section: Discussionmentioning

confidence: 99%

“…T‐cell PTLD are much less common. Case reports which document PTLD of T‐cell lineage have been published, but for the most part are not well characterized ( Lippman et al , 1987 ; Tsurumi et al , 1992 ; Rostaing et al , 1995 ; Garvin et al , 1988 ; Kemnitz et al , 1990 ; Pascual et al , 1992 ; Hacker et al , 1992 ; Audovin et al , 1989 ; Ross et al , 1994 ). Similiar to B‐cell PTLD, they mostly present as aggressive lymphomas exhibiting a rapidly fatal course.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Large granular lymphocyte leukaemia occurring after renal transplantation

et al. 1998

View full text Add to dashboard Cite

Summary. Post-transplantation lymphoproliferative disorders (PTLD) are a clinicopathologically heterogenous group of lymphoid proliferations. The majority are of B-cell origin and associated with Epstein-Barr virus (EBV) infection. In contrast, the development of T-cell PTLD is much less common and EBV does not appear to be involved in pathogenesis. In this report we describe three patients who developed large granular lymphocyte (LGL) leukaemia after renal transplantation. These patients had clonal expansionLGL. We were unable to detect CMV antigen or find evidence for EBV or human T-cell leukaemia/lymphoma virus genome in the LGL from these patients. These data show that LGL leukaemia should be included as one of the types of T-cell proliferations which can occur post transplant.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Large granular lymphocyte leukaemia occurring after renal transplantation

et al. 1998

View full text Add to dashboard Cite

show abstract

“…Even though retrospective studies with sufficient numbers of cases are not available, it seems that the histotype has no prognostic value and therefore would not influence therapeutic choice or treatment response [3,17]. Some extremely rare histological forms of PCNSL such as solitary intracranial plasmacytoma and intravascular lymphoma [18] have been described. Only 15 cases of the former have been reported, all of them with a prevalently meningeal localization.…”

Section: Pathology and Biologymentioning

confidence: 99%

Primary central nervous system lymphoma

Ferreri¹,

Reni²

2007

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Primary central nervous system lymphomas (PCNSL) are aggressive malignancies that arise in distinct anatomical sites, which display unique structural, biological and immunological conditions. So far, despite recent therapeutic advances, these malignancies exhibit one of the worst prognoses among all non-Hodgkin lymphomas (NHL). For a long time, radiotherapy (RT) has been the standard treatment, producing a response rate of 60-65% and a notable neurological improvement in most cases. However, relapse usually occurred within a few months after RT, with a median survival of 14 months and a 5-year survival of approximately 15-24%. Although the introduction of systemic chemotherapy has consistently improved survival, the prognosis of PCNSL is still dismal, with high rates of local relapse and consequent death. Defining the optimum therapeutic management is difficult because of potential selection biases in large retrospective reviews and the limited number of prospective studies. Although studies published on PCNSL are increasing, several therapeutic questions still remain unanswered after a decade of research.

show abstract